{"id":39667,"date":"2023-03-08T10:40:19","date_gmt":"2023-03-08T05:10:19","guid":{"rendered":"http:\/\/finservwealth.com\/jefferies-cuts-target-lowers-eps-estimates-of-cipla-flags-delay-in-fda-approvals\/"},"modified":"2023-03-08T10:40:19","modified_gmt":"2023-03-08T05:10:19","slug":"jefferies-cuts-target-lowers-eps-estimates-of-cipla-flags-delay-in-fda-approvals","status":"publish","type":"post","link":"https:\/\/finservwealth.com\/hi\/jefferies-cuts-target-lowers-eps-estimates-of-cipla-flags-delay-in-fda-approvals\/","title":{"rendered":"Jefferies cuts target, lowers EPS estimates of Cipla; flags delay in FDA approvals"},"content":{"rendered":"<p> Cipla#39;s largest Indian facilities including Goa and Indore are under the regulatory scanner, which could impact new launches in the medium term. It estimates the value of India business at Rs 680 per share.<\/p><div id=\"finse-2489191310\" class=\"finse-content finse-entity-placement\"><script async src=\"\/\/pagead2.googlesyndication.com\/pagead\/js\/adsbygoogle.js?client=ca-pub-9118214110898834\" crossorigin=\"anonymous\"><\/script><ins class=\"adsbygoogle\" style=\"display:block;\" data-ad-client=\"ca-pub-9118214110898834\" \ndata-ad-slot=\"\" \ndata-ad-format=\"auto\"><\/ins>\n<script> \n(adsbygoogle = window.adsbygoogle || []).push({}); \n<\/script>\n<\/div>\n<p><a href=\"https:\/\/www.moneycontrol.com\/news\/buzzing-stocks\/jefferies-cuts-target-lowers-eps-estimatescipla-flags-delayfda-approvals_16919951.html\" target=\"_blank\" class=\"feedzy-rss-link-icon\" rel=\"noopener\">Read More<\/a><\/p>\n<p>\u200b\u00a0Cipla#39;s largest Indian facilities including Goa and Indore are under the regulatory scanner, which could impact new launches in the medium term. It estimates the value of India business at Rs 680 per share. Cipla#39;s largest Indian facilities including Goa and Indore are under the regulatory scanner, which could impact new launches in the medium term. It estimates the value of India business at Rs 680 per share.\u00a0\u00a0Moneycontrol Latest News\u00a0<a href=\"https:\/\/www.moneycontrol.com\/news\/buzzing-stocks\/jefferies-cuts-target-lowers-eps-estimatescipla-flags-delayfda-approvals_16919951.html\" target=\"_blank\" class=\"feedzy-rss-link-icon\" rel=\"noopener\">Read More<\/a>\u00a0\u00a0<\/p>","protected":false},"excerpt":{"rendered":"<p><!-- wp:html --><\/p>\n<p> Cipla#39;s largest Indian facilities including Goa and Indore are under the regulatory scanner, which could impact new launches in the medium term. It estimates the value of India business at Rs 680 per share.<\/p>\n<p><a href=\"https:\/\/www.moneycontrol.com\/news\/buzzing-stocks\/jefferies-cuts-target-lowers-eps-estimatescipla-flags-delayfda-approvals_16919951.html\" target=\"_blank\" class=\"feedzy-rss-link-icon\" rel=\"noopener\">Read More<\/a><\/p>\n<p>\u200b\u00a0Cipla#39;s largest Indian facilities including Goa and Indore are under the regulatory scanner, which could impact new launches in the medium term. It estimates the value of India business at Rs 680 per share. Cipla#39;s largest Indian facilities including Goa and Indore are under the regulatory scanner, which could impact new launches in the medium term. It estimates the value of India business at Rs 680 per share.\u00a0\u00a0Moneycontrol Latest News\u00a0<a href=\"https:\/\/www.moneycontrol.com\/news\/buzzing-stocks\/jefferies-cuts-target-lowers-eps-estimatescipla-flags-delayfda-approvals_16919951.html\" target=\"_blank\" class=\"feedzy-rss-link-icon\" rel=\"noopener\">Read More<\/a>\u00a0\u00a0<\/p>\n<p><!-- \/wp:html --> Cipla#39;s largest Indian facilities including Goa and Indore are under the regulatory scanner, which could impact new launches in the medium term. It estimates the value of India business at Rs 680 per share.<\/p>","protected":false},"author":0,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"content-type":"","_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"neve_meta_sidebar":"","neve_meta_container":"","neve_meta_enable_content_width":"","neve_meta_content_width":0,"neve_meta_title_alignment":"","neve_meta_author_avatar":"","neve_post_elements_order":"","neve_meta_disable_header":"","neve_meta_disable_footer":"","neve_meta_disable_title":"","_themeisle_gutenberg_block_has_review":false,"footnotes":""},"categories":[70],"tags":[],"class_list":["post-39667","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-latest-news"],"jetpack_featured_media_url":"https:\/\/www.moneycontrol.com\/news_image_files\/2023\/200x200\/p\/pharma_tablet_injection_capsule_200.jpg","_links":{"self":[{"href":"https:\/\/finservwealth.com\/hi\/wp-json\/wp\/v2\/posts\/39667","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/finservwealth.com\/hi\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/finservwealth.com\/hi\/wp-json\/wp\/v2\/types\/post"}],"replies":[{"embeddable":true,"href":"https:\/\/finservwealth.com\/hi\/wp-json\/wp\/v2\/comments?post=39667"}],"version-history":[{"count":0,"href":"https:\/\/finservwealth.com\/hi\/wp-json\/wp\/v2\/posts\/39667\/revisions"}],"wp:attachment":[{"href":"https:\/\/finservwealth.com\/hi\/wp-json\/wp\/v2\/media?parent=39667"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/finservwealth.com\/hi\/wp-json\/wp\/v2\/categories?post=39667"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/finservwealth.com\/hi\/wp-json\/wp\/v2\/tags?post=39667"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}